IRONWOOD PHARMACEUTICALS INC (IRWD): auditor change — Ironwood dismisses EY as auditor; appoints KPMG; prior adverse ICFR opinion cited

IRONWOOD PHARMACEUTICALS INC

Dismissed Ernst & Young as independent auditor on July 3, 2025; no disagreements during fiscal 2023 and 2024.
EY's report on internal controls for fiscal 2024 contained adverse opinion due to material weaknesses in entity-level and ITGC controls.
Material weaknesses also impacted financial close process and expenditure controls; no restatement required.
Audit Committee appointed KPMG as new independent auditor effective immediately for FY 2025.
EY agreed with disclosures; furnished letter to SEC dated July 10, 2025.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

IRONWOOD PHARMACEUTICALS INC dismissed Ernst & Young LLP as its auditor.

Action: dismissal
Auditor: Ernst & Young LLP
Successor: KPMG LLP

Exact text from the filing

On July 3, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

IRONWOOD PHARMACEUTICALS INC engaged KPMG LLP as its auditor.

Action: engagement
Auditor: KPMG LLP

Exact text from the filing

On July 3, 2025, the Audit Committee approved the appointment of KPMG to serve as the Company’s new independent registered public accounting firm, effective immediately, for the fiscal year ending December 31, 2025.

View on SEC.gov

Browse all auditor changes →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-25-066986

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.